Atlas Trials

A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

Clinical trial NCT02611505 · COMPLETED

Trial details

NCT number
NCT02611505
Sponsor
Janssen Research & Development, LLC
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatic ImpairmentNormal Hepatic Function
Start date
2015-11-30
Primary completion
2017-02-27
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.